| Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis J Golay, L Zaffaroni, T Vaccari, M Lazzari, GM Borleri, S Bernasconi, ... Blood, The Journal of the American Society of Hematology 95 (12), 3900-3908, 2000 | 795 | 2000 |
| Complement activation determines the therapeutic activity of rituximab in vivo N Di Gaetano, E Cittera, R Nota, A Vecchi, V Grieco, E Scanziani, M Botto, ... The Journal of Immunology 171 (3), 1581-1587, 2003 | 723 | 2003 |
| From the bench to the bedside: ways to improve rituximab efficacy G Cartron, H Watier, J Golay, P Solal-Celigny Blood 104 (9), 2635-2642, 2004 | 673 | 2004 |
| Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. F Breviario, EM d'Aniello, J Golay, G Peri, B Bottazzi, A Bairoch, ... Journal of Biological Chemistry 267 (31), 22190-22197, 1992 | 640 | 1992 |
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 J Golay, M Lazzari, V Facchinetti, S Bernasconi, G Borleri, T Barbui, ... Blood, The Journal of the American Society of Hematology 98 (12), 3383-3389, 2001 | 555 | 2001 |
| The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells E Bourke, D Bosisio, J Golay, N Polentarutti, A Mantovani Blood 102 (3), 956-963, 2003 | 518 | 2003 |
| Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility N Perico, F Casiraghi, M Introna, E Gotti, M Todeschini, RA Cavinato, ... Clinical Journal of the American Society of Nephrology 6 (2), 412-422, 2011 | 367 | 2011 |
| Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin F Breviario, L Caveda, M Corada, I Martin-Padura, P Navarro, J Golay, ... Arteriosclerosis, thrombosis, and vascular biology 15 (8), 1229-1239, 1995 | 345 | 1995 |
| Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes VV Alles, B Bottazzi, G Peri, J Golay, M Introna, A Mantovani | 331 | 1994 |
| M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro M Leidi, E Gotti, L Bologna, E Miranda, M Rimoldi, A Sica, M Roncalli, ... The Journal of Immunology 182 (7), 4415-4422, 2009 | 323 | 2009 |
| Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity A Pievani, G Borleri, D Pende, L Moretta, A Rambaldi, J Golay, M Introna Blood, The Journal of the American Society of Hematology 118 (12), 3301-3310, 2011 | 308 | 2011 |
| Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ... Blood, The Journal of the American Society of Hematology 122 (20), 3482-3491, 2013 | 276 | 2013 |
| Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone N Di Gaetano, Y Xiao, E Erba, R Bassan, A Rambaldi, J Golay, M Introna British journal of haematology 114 (4), 800-809, 2001 | 276 | 2001 |
| Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study M Introna, G Borleri, E Conti, M Franceschetti, AM Barbui, R Broady, ... haematologica 92 (7), 952-959, 2007 | 267 | 2007 |
| Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients M Introna, G Lucchini, E Dander, S Galimberti, A Rovelli, A Balduzzi, ... Biology of blood and marrow transplantation 20 (3), 375-381, 2014 | 263 | 2014 |
| The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. JT Golay, EA Clark, PC Beverley Journal of immunology (Baltimore, Md.: 1950) 135 (6), 3795-3801, 1985 | 248 | 1985 |
| Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population G Lucchini, M Introna, E Dander, A Rovelli, A Balduzzi, S Bonanomi, ... Biology of blood and marrow transplantation 16 (9), 1293-1301, 2010 | 238 | 2010 |
| Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and … L Bologna, E Gotti, M Manganini, A Rambaldi, T Intermesoli, M Introna, ... The Journal of Immunology 186 (6), 3762-3769, 2011 | 228 | 2011 |
| Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts C Capelli, M Domenghini, G Borleri, P Bellavita, R Poma, A Carobbio, ... Bone marrow transplantation 40 (8), 785-791, 2007 | 215 | 2007 |
| Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes M Franceschetti, A Pievani, G Borleri, L Vago, K Fleischhauer, J Golay, ... Experimental hematology 37 (5), 616-628. e2, 2009 | 198 | 2009 |
